Adjuvant ipilimumab for stage III melanoma: the patient voice
Mené sur 951 patients atteints d'un mélanome de stade III ayant subi une résection complète, cet essai international de phase III évalue l'efficacité, du point de vue de la qualité de vie, d'un traitement adjuvant par ipilimumab
The therapeutic landscape for the management of patients with resected high-risk malignant melanoma is evolving rapidly; however, it remains an important clinical challenge. Adjuvant interferon has significant toxicities and limited efficacy, and drugs currently under investigation, targeting PD-1, BRAF, MEK, and CTLA-4, have the potential to be more effective. EORTC 18071, a randomised, placebo-controlled, double-blind phase 3 trial of adjuvant ipilimumab (anti CTLA-4 immunotherapy) compared with placebo in patients with stage III melanoma, showed longer recurrence-free survival (hazard ratio [HR] 0·76; p=0·001), and overall survival (HR 0·72; p<0·001) for patients treated with ipilimumab compared with placebo.
The Lancet Oncology , commentaire, 2016